Astragaloside IV regulates autophagy-mediated proliferation and apoptosis in a rat model of PCOS by activating the PPARγ pathway

Document Type : Original Article

Authors

Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou 310000, China

10.22038/ijbms.2022.64475.14179

Abstract

Objective(s): Astragaloside IV (AS-IV) is a bioactive saponin with a wide range of pharmacological effects. This study was aimed at investigating its potential effect on polycystic ovary syndrome (PCOS). 
Materials and Methods: Female Sprague-Dawley rats were randomly divided into five groups (control, PCOS, PCOS+AS-IV 20 mg/kg, PCOS+AS-IV 40 mg/kg, and PCOS+AS-IV 80 mg/kg). The pathological injury level of rat ovary was observed with hematoxylin-eosin (H&E) staining; enzyme-linked immunosorbent assay (ELISA) kit was utilized to measure the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone in rat serum; western blot detected autophagy-associated or peroxisome proliferator-activated receptor γ (PPARγ) pathway-related protein expression; immunofluorescence was performed to observe LC3 level in rat ovarian tissue. After co-treatment with AS-IV and PPARγ inhibitor, the proliferation in ovarian granulosa cell line KGN was examined employing cell counting kit-8 (CCK-8), EdU staining, and colony formation; cell apoptosis was observed with TdT-mediated dUTP nick-end labeling (TUNEL); apoptosis-related protein expression was assayed by western blot. 
Results: Treatment with AS-IV inhibited the ovarian pathological damage in PCOS rats. It also promoted the level of autophagy and activated PPARγ signaling in the rat PCOS model. In KGN cells, the level of autophagy and expression of PPARγ-related proteins were also elevated by AS-IV treatment. Furthermore, AS-IV facilitated autophagy, thus inhibiting KGN cell proliferation and promoting its apoptosis, through activating the PPARγ signaling pathway. 
Conclusion: AS-IV-activated PPARγ inhibits proliferation and promotes the apoptosis of ovarian granulosa cells, enhancing ovarian function in rats with PCOS.

Keywords


1. Yaba A, Demir N. The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS). J Ovarian Res 2012; 5:38.
2. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 2016; 14:38-54.
3. Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012; 30:496-506.
4. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14:270-284.
5. Wojciechowska A, Osowski A, Jozwik M, Gorecki R, Rynkiewicz A, Wojtkiewicz J. Inositols’ importance in the improvement of the endocrine-metabolic profile in PCOS. Int J Mol Sci 2019; 20.
6. McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med 2016; 375:54-64.
7. Meier RK. Polycystic ovary syndrome. Nurs Clin North Am 2018; 53:407-420.
8. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141-146.
9. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038-2049.
10. Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids 2013; 78:782-785.
11. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv Clin Exp Med 2017; 26:359-367.
12. Jin M, Zhao K, Huang Q, Shang P. Structural features and biological activities of the polysaccharides from Astragalus membranaceus. Int J Biol Macromol 2014; 64:257-266.
13. Shahzad M, Shabbir A, Wojcikowski K, Wohlmuth H, Gobe GC. The Anti-oxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease. Curr Drug Targets 2016; 17:1331-1340.
14. Li L, Hou X, Xu R, Liu C, Tu M. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol 2017; 31:17-36.
15. Ren S, Zhang H, Mu Y, Sun M, Liu P. Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med 2013; 33:413-416.
16. Wang X, Gao Y, Tian N, Wang T, Shi Y, Xu J, et al. Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-kappaB p65 axis. Sci Rep 2019; 9:323.
17. Zhu Y, Qian X, Li J, Lin X, Luo J, Huang J, et al. Astragaloside-IV protects H9C2(2-1) cardiomyocytes from high glucose-induced injury via miR-34a-mediated autophagy pathway. Artif Cells Nanomed Biotechnol 2019; 47:4172-4181.
18. Zhang C, Hu J, Wang W, Sun Y, Sun K. HMGB1-induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS. FASEB J 2020; 34:9563-9574.
19. Tao T, Xu H. Autophagy and obesity-related reproductive dysfunction. Adv Exp Med Biol 2020; 1207:463-466.
20. Wang X, Xu W, Chen H, Li W, Li W, Zhu G. Astragaloside IV prevents Abeta1-42 oligomers-induced memory impairment and hippocampal cell apoptosis by promoting PPARgamma/BDNF signaling pathway. Brain Res 2020; 1747:147041.
21. Wang X, Wang Y, Hu JP, Yu S, Li BK, Cui Y, et al. Astragaloside IV, a natural PPARγ agonist, reduces Aβ production in alzheimer’s disease through inhibition of BACE1. Mol Neurobiol 2017; 54:2939-2949.
22. Song MT, Ruan J, Zhang RY, Deng J, Ma ZQ, Ma SP. Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice via the PPARγ/NF-κB/NLRP3 inflammasome axis. Acta Pharmacol Sin 2018; 39:1559-1570.
23. Xing L, Fang J, Zhu B, Wang L, Chen J, Wang Y, et al. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy. Life Sci 2021; 269:119068.
24. Liu J, Yao Q, Xiao L, Ma W, Li F, Lai B, et al. PPARgamma induces NEDD4 gene expression to promote autophagy and insulin action. FEBS J 2020; 287:529-545.
25. Liu J, Yao Q, Xiao L, Ma W, Li F, Lai B, et al. PPARγ induces NEDD4 gene expression to promote autophagy and insulin action. Febs J 2020; 287:529-545.
26. Cai Z, He S, Li T, Zhao L, Zhang K. Plumbagin inhibits proliferation and promotes apoptosis of ovarian granulosa cells in polycystic ovary syndrome by inactivating PI3K/Akt/mTOR pathway. Anim Cells Syst (Seoul) 2020; 24:197-204.
27. Liu YL, Zhang QZ, Wang YR, Fu LN, Han JS, Zhang J, et al. Astragaloside IV improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4/NF-κB signaling pathway. Front Pharmacol 2020; 11:605064.
28. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115:e500-503.
29. Fan Y, Fan H, Zhu B, Zhou Y, Liu Q, Li P. Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats. BMC Complement Altern Med 2019; 19:355.
30. Zhang Z, Wang J, Zhu Y, Zhang H, Wang H. Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism. Mol Med Rep 2019; 20:4612-4622.
31. Nejati A, Shahri MPK, Farahvash T. Astragalus hamosus Acts as an insulin sensitizer through the treatment of polycystic ovary syndrome rat models by affecting IRS1 expression. Endocr Metab Immune Disord Drug Targets 2021.
32. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37:467-520.
33. Khattak M, Sultana N, Usman R, Khattak U, Zafar U, Salman H. Luteinizing Hormone To Follicle Stimulating Hormone Ratio In Patients With Polycystic Ovary Syndrome. J Ayub Med Coll Abbottabad 2020; 32:255-258.
34. Y DP, Valsala Gopalakrishnan A. gamma-Linolenic acid ameliorates DHEA induced pro-inflammatory response in polycystic ovary syndrome via PPAR-gamma signaling in rats. Reprod Biol 2020; 20:348-356.
35. Lu Y, Sun Y, Zhu J, Yu L, Jiang X, Zhang J, et al. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-gamma and inhibiting Nrf2 pathway. Cell Death Dis 2018; 9:15.
36. Kobayashi M, Yoshino O, Nakashima A, Ito M, Nishio K, Ono Y, et al. Inhibition of autophagy in theca cells induces CYP17A1 and PAI-1 expression via ROS/p38 and JNK signalling during the development of polycystic ovary syndrome. Mol Cell Endocrinol 2020; 508:110792.
37. Li X, Qi J, Zhu Q, He Y, Wang Y, Lu Y, et al. The role of androgen in autophagy of granulosa cells from PCOS. Gynecol Endocrinol 2019; 35:669-672.
38. Shan H, Zheng X, Li M. The effects of Astragalus membranaceus active extracts on autophagy-related diseases. Int J Mol Sci 2019; 20.
39. Chu CW, Ko HJ, Chou CH, Cheng TS, Cheng HW, Liang YH, et al. Thioridazine enhances P62-mediated autophagy and apoptosis through Wnt/beta-catenin signaling pathway in glioma cells. Int J Mol Sci 2019; 20:473.
40. Zhang L, Zhou J, Qin X, Huang H, Nie C. Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGFbeta1mediated PI3K and MAPK pathways. Oncol Rep 2019; 41:2975-2986.
41. Zhao Y, Wang L, Wang Y, Dong S, Yang S, Guan Y, et al. Astragaloside IV inhibits cell proliferation in vulvar squamous cell carcinoma through the TGF-beta/Smad signaling pathway. Dermatol Ther 2019; 32:e12802.
42. Zhong J, Gong W, Chen J, Qing Y, Wu S, Li H, et al. Micheliolide alleviates hepatic steatosis in db/db mice by inhibiting inflammation and promoting autophagy via PPAR-gamma-mediated NF-small ka, CyrillicB and AMPK/mTOR signaling. Int Immunopharmacol 2018; 59:197-208.
43. Peng Y, Guo L, Gu A, Shi B, Ren Y, Cong J, et al. Electroacupuncture alleviates polycystic ovary syndrome-like symptoms through improving insulin resistance, mitochondrial dysfunction, and endoplasmic reticulum stress via enhancing autophagy in rats. Mol Med 2020; 26:73.
44. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8:741-752.
45. Yang D, Zhang M, Gan Y, Yang S, Wang J, Yu M, et al. Involvement of oxidative stress in ZnO NPs-induced apoptosis and autophagy of mouse GC-1 spg cells. Ecotoxicol Environ Saf 2020; 202:110960.
46. Gan Y, Yang D, Yang S, Wang J, Wei J, Chen J. Di-2-ethylhexyl phthalate (DEHP) induces apoptosis and autophagy of mouse GC-1 spg cells. Environ Toxicol 2020; 35:292-299.